The FDA inspection found a lack of assurance of sterility and identified GMP violations that could impact product quality and sterility. As a result, the affected product is being recalled.
Regulatorische Updates24. Aug. 2026•1 Min. Lesezeit
FDA Identifies GMP Violations Affecting Sterility Assurance
An FDA inspection uncovered GMP violations that may compromise product sterility and quality, prompting a recall.
Zusammengestellt vom PharmaCountry-Team · Quelle: FDA.gov
Bewertungen
(0)
(0)
(0)
(0)
(0)
Weitere Artikel
Alle Einblicke anzeigenStudien & Berichte
Global Finished Dosage Manufacturing Landscape 2026
5. Okt. 2026
Regulatorische UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28. Sept. 2026
AnalysePharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28. Sept. 2026
Bewertung hinterlassen